Paper39771997
Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.
Wang J and 5 others. Vaccines (Basel), 2024. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review. Papers, record 39771997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39771997
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References161
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32992617 | The Importance of Evaluating the Lot-to-Lot Batch Consistency of Commercial Multi-Walled Carbon Nanotube Products. | Nanomaterials (Basel) | 2020 | https://conductscience.org/library/papers/32992617 | PubMed |
| 2 | 20822351 | Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. | Expert Rev Vaccines | 2010 | https://conductscience.org/library/papers/20822351 | PubMed |
| 3 | 33249249 | Co-adsorption of synthetic Mincle agonists and antigen to silica nanoparticles for enhanced vaccine activity: A formulation approach to co-delivery. | Int J Pharm | 2021 | https://conductscience.org/library/papers/33249249 | PubMed |
| 4 | 33529034 | Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Streptococcus Vaccine Delivery. | J Med Chem | 2021 | https://conductscience.org/library/papers/33529034 | PubMed |
| 5 | 29983563 | Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach. | Int J Nanomedicine | 2018 | https://conductscience.org/library/papers/29983563 | PubMed |
| 6 | 28943194 | Intradermal vaccination with hollow microneedles: A comparative study of various protein antigen and adjuvant encapsulated nanoparticles. | J Control Release | 2017 | https://conductscience.org/library/papers/28943194 | PubMed |
| 7 | 37111723 | Pulmonary Application of Novel Antigen-Loaded Chitosan Nano-Particles Co-Administered with the Mucosal Adjuvant C-Di-AMP Resulted in Enhanced Immune Stimulation and Dose Sparing Capacity. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/37111723 | PubMed |
| 8 | 23657437 | Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. | Nanoscale | 2013 | https://conductscience.org/library/papers/23657437 | PubMed |
| 9 | 15628980 | Protective effect of neonatal BCG vaccines against tuberculous meningitis. | Bosn J Basic Med Sci | 2004 | https://conductscience.org/library/papers/15628980 | PubMed |
| 10 | 38164481 | Enhancement of the immunogenicity of a Mycobacterium tuberculosis fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants as prophylactic vaccine after nasal administration in mice. | Iran J Basic Med Sci | 2024 | https://conductscience.org/library/papers/38164481 | PubMed |
| 11 | 33811104 | Glycolipid-Containing Nanoparticle Vaccine Engages Invariant NKT Cells to Enhance Humoral Protection against Systemic Bacterial Infection but Abrogates T-Independent Vaccine Responses. | J Immunol | 2021 | https://conductscience.org/library/papers/33811104 | PubMed |
| 12 | 31260754 | Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles. | J Control Release | 2019 | https://conductscience.org/library/papers/31260754 | PubMed |
| 13 | 31579445 | Enhancing immunogenicity of novel multistage subunit vaccine of Mycobacterium tuberculosis using PLGA:DDA hybrid nanoparticles and MPLA: Subcutaneous administration. | Iran J Basic Med Sci | 2019 | https://conductscience.org/library/papers/31579445 | PubMed |
| 14 | 31089379 | Formulation and Optimization of a New Cationic Lipid-Modified PLGA Nanoparticle as Delivery System for Mycobacterium tuberculosis HspX/EsxS Fusion Protein: An Experimental Design. | Iran J Pharm Res | 2019 | https://conductscience.org/library/papers/31089379 | PubMed |
| 15 | 24248387 | Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/24248387 | PubMed |
| 16 | 30733717 | Nanoparticle-Based Vaccines Against Respiratory Viruses. | Front Immunol | 2019 | https://conductscience.org/library/papers/30733717 | PubMed |
| 17 | 22328935 | Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. | PLoS One | 2012 | https://conductscience.org/library/papers/22328935 | PubMed |
| 18 | 34264684 | Lipid-Based Nanoparticles for Delivery of Vaccine Adjuvants and Antigens: Toward Multicomponent Vaccines. | Mol Pharm | 2021 | https://conductscience.org/library/papers/34264684 | PubMed |
| 19 | 20934457 | Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation. | Vaccine | 2010 | https://conductscience.org/library/papers/20934457 | PubMed |
| 20 | 32206497 | Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. | 3 Biotech | 2020 | https://conductscience.org/library/papers/32206497 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42963803 | Current strategies and challenges in vaccine platforms for Newcastle Disease Virus. | Trop Dis Travel Med Vaccines | 2026 | https://conductscience.org/library/papers/42963803 | PubMed |
| 42220545 | Nano-adjuvants enhance the immunogenicity and safety of infectious bursal disease virus vaccines: a comprehensive review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42220545 | PubMed |
| 41770791 | A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/41770791 | PubMed |
| 41746080 | Advances in Nanoparticles as Vaccine Adjuvants. | Vaccines (Basel) | 2026 | https://conductscience.org/library/papers/41746080 | PubMed |
| 41304797 | Advanced Nanosystems and Emerging Therapies: Innovations in Tuberculosis Treatment and Drug Resistance. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41304797 | PubMed |
| 40629425 | Chitosan-based formulations for therapeutic applications. A recent overview. | J Biomed Sci | 2025 | https://conductscience.org/library/papers/40629425 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39771997
GET https://conductscience.org/api/papers/v1/39771997/references?page=2